Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-04-09, Stock:JNJ, The news for the past five days is as follows:
2018-04-02: NEWS1: U.S. Justice Department seeks role in opioid settlement talks.NEWS2: Why I Won&apos;t Buy Ethereum.NEWS3: DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Johnson & Johnson and Encourages Investors to Contact The Firm.NEWS4: Why Geron Corporation Stock Is Falling Today.NEWS5: Why Geron Corporation Stock Is Falling Today.NEWS6: EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Johnson & Johnson of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 9, 2018 - JNJ.NEWS7: How an ill-advised tweet became a nightmare for a Fox News show.NEWS8: iShares Russell 1000 ETF Experiences Big Outflow.NEWS9: iShares Russell 1000 ETF Experiences Big Outflow.NEWS10: Why Geron Corporation Stock Is Falling Today.NEWS11: Shire's Stock Continues to Rise as Takeda Sets Eyes On it.NEWS12: Shire's Stock Continues to Rise as Takeda Sets Eyes On it.NEWS13: How Novartis’s Alcon Performed in 4Q17 and Fiscal 2017.NEWS14: How Novartis’s Alcon Performed in 4Q17 and Fiscal 2017.NEWS15: How Eli Lilly’s Neuroscience Products Performed in 4Q17.NEWS16: How Eli Lilly’s Neuroscience Products Performed in 4Q17.NEWS17: How Did Sandoz Perform in 4Q17 and Fiscal 2017?.NEWS18: How Did Sandoz Perform in 4Q17 and Fiscal 2017?.NEWS19: Are Short-Sellers Right About Geron Corporation?.NEWS20: Are Short-Sellers Right About Geron Corporation?.NEWS21: Are Short-Sellers Right About Geron Corporation?.
2018-04-03: NEWS1: Pfizer Reportedly In Talks With P&G On Consumer Business Sale.NEWS2: Pfizer Reportedly In Talks With P&G On Consumer Business Sale.NEWS3: The 10 Best Stocks to Buy for April.NEWS4: The 10 Best Stocks to Buy for April.NEWS5: IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Johnson & Johnson And Reminds Investors To Contact The Firm.NEWS6: Johnson & Johnson Stock on March 29, 2018.NEWS7: Markets Right Now: Late rally sends US stock indexes higher.NEWS8: The Klein Law Firm Notifies Investors of Commencement of a Class Action Filed on Behalf of Johnson & Johnson Shareholders and a Lead Plaintiff Deadline of April 9, 2018 (JNJ).NEWS9: Markets Right Now: Stocks move solidly higher on Wall Street.NEWS10: Markets Right Now: Stocks move solidly higher on Wall Street.NEWS11: Pfizer in talks with P&G for consumer health unit sale - CNBC.NEWS12: The brand boycott of Laura Ingraham’s Fox News show barely registers with consumers.NEWS13: The brand boycott of Laura Ingraham’s Fox News show barely registers with consumers.NEWS14: Pfizer in talks with P&G on sale of its consumer business, though they are far apart on price: Sources.NEWS15: Pfizer in talks with P&G on sale of its consumer business, though they are far apart on price: Sources.NEWS16: Pfizer in talks with P&G for consumer health unit sale - CNBC.NEWS17: What Analysts Recommend for Novartis in March 2018.NEWS18: What Analysts Recommend for Novartis in March 2018.NEWS19: Will These Drugs Reach Blockbuster Status?.NEWS20: Will These Drugs Reach Blockbuster Status?.NEWS21: April 9th Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Johnson & Johnson (JNJ).
2018-04-04: NEWS1: 5-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Johnson & Johnson And Reminds Investors To Contact The Firm.NEWS2: EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Johnson & Johnson of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 9, 2018 – JNJ.NEWS3: NYSE trader: Here are the real risks to the U.S. economy.NEWS4: Allergan's Vraylar Meets Endpoints in Bipolar I Phase III.NEWS5: Allergan's Vraylar Meets Endpoints in Bipolar I Phase III.NEWS6: AstraZeneca's (AZN) Bydureon Gets FDA Nod for Expanded Use.NEWS7: AstraZeneca's (AZN) Bydureon Gets FDA Nod for Expanded Use.NEWS8: Johnson & Johnson’s Quarterly Revenue Trend in 2017.NEWS9: J&J Jury Set to Weigh Banker's Claims Baby Powder Caused Cancer.NEWS10: Bristol-Myers Squibb Company (BMY) Ex-Dividend Date Scheduled for April 05, 2018.NEWS11: Bristol-Myers Squibb Company (BMY) Ex-Dividend Date Scheduled for April 05, 2018.NEWS12: Johnson & Johnson’s Valuation in March 2018.NEWS13: Which Big Pharma CEOs Least Deserved Their Big Pay Increases?.NEWS14: Which Big Pharma CEOs Least Deserved Their Big Pay Increases?.NEWS15: Analysts’ Recommendations for Johnson & Johnson in March 2018.NEWS16: Which Big Pharma CEOs Least Deserved Their Big Pay Increases?.NEWS17: The boycott of Laura Ingraham’s Fox News show barely registered with consumers (with one exception).NEWS18: The boycott of Laura Ingraham’s Fox News show barely registered with consumers (with one exception).NEWS19: Smith & Nephew Names Namal Nawana CEO - Quick Facts.NEWS20: Smith & Nephew Names Namal Nawana CEO - Quick Facts.
2018-04-05: NEWS1: Corrected: J&J loses trial over claims linking cancer to asbestos in talc.NEWS2: UPDATE 2-J&J loses trial over claims linking cancer to asbestos in talc.NEWS3: J&J Ordered to Pay $37 Million Over Banker's Talc Cancer Claims.NEWS4: J&J Must Pay Millions Over Banker's Baby Powder Cancer Claim.NEWS5: J&J Ordered to Pay $37 Million Over Banker's Talc Cancer Claims.NEWS6: FDA Refuses Alkermes Depression Drug Review: 4 Stocks in Focus.NEWS7: FDA Refuses Alkermes Depression Drug Review: 4 Stocks in Focus.NEWS8: Wall Street Brushes Off Trade War Fears: Top 5 Gainers.NEWS9: Wall Street Brushes Off Trade War Fears: Top 5 Gainers.NEWS10: FDA Refuses Alkermes Depression Drug Review: 4 Stocks in Focus.NEWS11: 5 Dividend Growth Stocks With Upside To Analyst Targets.NEWS12: 5 Dividend Growth Stocks With Upside To Analyst Targets.NEWS13: 3 Emerging Technologies Set to Transform the Pharma World.NEWS14: Johnson & Johnson’s Business Segments in 2017.NEWS15: Alkermes' Bad News Could Be Good News for Johnson & Johnson.NEWS16: Alkermes' Bad News Could Be Good News for Johnson & Johnson.NEWS17: Alkermes&apos; Bad News Could Be Good News for Johnson & Johnson.
2018-04-06: NEWS1: NJ Man Wins $37 Million in J&J Baby Powder Case.NEWS2: Stocks dive as US proposes more China tariffs; Dow falls 620.NEWS3: Stocks skid again after US proposes more China tariffs.NEWS4: APRIL 9 DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Johnson & Johnson And Reminds Investors To Contact The Firm.NEWS5: The Zacks Analyst Blog Highlights: Tandem Diabetes Care, Addus HomeCare, Tailored Brands, Tellurian and Johnson & Johnson.NEWS6: The Zacks Analyst Blog Highlights: Tandem Diabetes Care, Addus HomeCare, Tailored Brands, Tellurian and Johnson & Johnson.NEWS7: 4 Drug/Biotech Stocks to Buy Ahead of World Health Day.NEWS8: 4 Drug/Biotech Stocks to Buy Ahead of World Health Day.NEWS9: MARKETS: Watch out for the 'Kudlow Put' round 2 and the Chinese tariff tantrum.NEWS10: The Top 5 Johnson & Johnson Shareholders (JNJ).NEWS11: Can Been-There Biotech Entrepreneur Arie Belldegrun Do It Yet Again?.NEWS12: Can Been-There Biotech Entrepreneur Arie Belldegrun Do It Yet Again?.NEWS13: 4 Drug/Biotech Stocks to Buy Ahead of World Health Day.NEWS14: The Zacks Analyst Blog Highlights: Tandem Diabetes Care, Addus HomeCare, Tailored Brands, Tellurian and Johnson & Johnson.NEWS15: Can Been-There Biotech Entrepreneur Arie Belldegrun Do It Yet Again?.NEWS16: These Alphabet-Backed Biotech Startups Went Public In 1Q18.NEWS17: JNJ EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Johnson & Johnson and a Lead Plaintiff Deadline of April 9, 2018.NEWS18: 3 Emerging Technologies Set to Transform the Pharma World.NEWS19: 3 Emerging Technologies Set to Transform the Pharma World.NEWS20: J&J, Imerys Ordered To Pay $37 Mln In Case Over Talc Cancer Risks.NEWS21: J&J, Imerys Ordered To Pay $37 Mln In Case Over Talc Cancer Risks.NEWS22: J&J loses trial over claims linking cancer to asbestos in talc.

Answer: Rise